Lee v. Frost

CourtDistrict Court, S.D. Florida
DecidedAugust 31, 2021
Docket1:21-cv-20885
StatusUnknown

This text of Lee v. Frost (Lee v. Frost) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lee v. Frost, (S.D. Fla. 2021).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA

CASE NO. 21-20885-CIV-ALTONAGA/Torres

SAMMY LEE, et al.,

Plaintiffs, v.

PHILLIP FROST, et al.,

Defendants. ______________________/

ORDER THIS CAUSE came before the Court on Defendants’ Motion to Dismiss Plaintiffs’ Verified Shareholder Derivative Consolidated Amended Complaint [ECF No. 62], filed on May 24, 2021.1 Plaintiffs, Sammy Lee and Andy Yu, filed a Response in Opposition [ECF No. 63] to the Motion; to which Defendants filed a Reply [ECF No. 68]. The Court has carefully considered the Consolidated Amended Complaint (“CAC”) [ECF No. 61], the parties’ written submissions, the record, and applicable law. For the following reasons, the Motion is granted. I. BACKGROUND This shareholder derivative action arises from OPKO’s alleged failure to diversify its Board of Directors and executive management team. (See generally CAC). Plaintiffs are shareholders of OPKO common stock. (See id. ¶¶ 16–17). OPKO is a Delaware corporation with its principal place of business in Miami, Florida and is publicly listed on the NASDAQ. (See id.

1 Defendants include Phillip Frost, Adam Logal, Jane H. Hsiao, Steven D. Rubin, Robert S. Fishel, Richard M. Krasno, Richard A. Lerner, John A. Paganelli, Richard C. Pfenniger, Jr., and Alice Lin-Tsing Yu, and Nominal Defendant OPKO Health, Inc. (“OPKO”) (collectively, “Defendants” for purposes of this Order). (See Mot. 2). The Court uses the pagination generated by the electronic CM/ECF database, which appears in the headers of all court filings. ¶ 18). OPKO is a diversified healthcare company engaged in both the diagnostics and pharmaceuticals business. (See id. ¶ 2). Defendants, Phillip Frost, Adam Logal, Jane H. Hsiao, Steven D. Rubin, Robert S. Fishel, Richard M. Krasno, Richard A. Lerner, John A. Paganelli, Richard C. Pfenniger, Jr., and Alice

Lin-Tsing Yu (the “Individual Defendants”) are members of OPKO’s Board. (See id. ¶¶ 19–48). The Board “assumes accountability for confirming that OPKO follows federal and state laws that prohibit racial discrimination.” (Id. ¶ 87). Frost is also OPKO’s CEO and Chairman (see id. ¶ 19); and Logal serves as its Senior Vice President, CFO, Chief Accounting Officer, and Treasurer (see id. ¶ 22). In addition, Hsiao is OPKO’s Chief Technical Officer and Vice-Chairman (see id. ¶ 25), while Rubin is the Executive Vice President of Administration (see id. ¶ 28). Krasno, Paganelli, and Pfenniger serve on the Board’s Audit Committee. (See id. ¶¶ 34, 40, 43). The Audit Committee oversees the company’s audits, reviews its internal controls, ensures “the integrity of [OPKO]’s financial statements[,]” and ensures “compliance with legal and regulatory requirements[.]” (Id. ¶ 72 (alterations added)). Fishel, Krasno, and Pfenniger serve

on the Board’s Succession Planning Committee, which recommends to the Board candidates for executive management positions. (See id. ¶¶ 31, 34, 43, 70–71). Lerner and Paganelli also serve on the Board’s Corporate Governance and Nominating Committee (see id. ¶¶ 37, 40), which “identif[ies] individuals qualified to become Board of Directors members, consistent with criteria approved by the Board of Directors[;]” and has “sole responsibility” to formally recommend new Board candidates. (Id. ¶ 69 (alterations added)). Further, OPKO’s Code of Conduct states “discrimination is not tolerated” and advises that employment decisions will not be based on factors such as “race” or “color[.]” (Id. ¶ 64 (alteration added)). The Code of Conduct applies to all OPKO employees, including Board members and executive officers, and instructs employees to report suspected Code violations to their supervisors. (See id. ¶¶ 60–61, 63, 67). Plaintiffs allege the Individual Defendants have “repeatedly refus[ed] to nominate, appoint, and/or hire Black or Latinx individuals or other underrepresented minorities to the Board or Black

individuals to the executive management team[.]” (Id. ¶ 7 (alterations added)). Specifically, Plaintiffs allege that, despite OPKO’s purported commitment to “a healthy work place[,]” “zero Black or Latinx individuals currently reside on [OPKO]’s Board and zero Black individuals work on [OPKO]’s executive management team.” (Id. (alterations added; emphasis omitted; quotation marks omitted); see also id. ¶ 86). “Instead, the overwhelming majority are . . . White men.” (Id. ¶ 87 (alteration added)). This lack of diversity is particularly significant given other companies’ recent social justice initiatives. (See id. ¶¶ 79–85). In order to maintain the Individual Defendants’ control of OPKO and to “keep Black, Latinx, and other underrepresented individuals off of the Board[,]” OPKO does not limit the number of terms a Board member can serve. (Id. ¶ 13 (alteration added); see also id. ¶ 91). For

example, at least half of the current Board members have been serving for over 13 years. (See id. ¶ 91). These policies are not in OPKO’s best interests, as studies show investors view long-tenured directors as cause for concern and companies with diverse boards are more likely to experience higher profits. (See id. ¶¶ 11, 90). As further proof that the Individual Defendants have perpetuated a non-diverse and non- inclusive corporate culture, Plaintiffs cite “numerous complaints regarding the lack of room for growth based on merit via reviews left by former and current employees of OPKO on websites such as Niche, Glassdoor, and Indeed.” (Id. ¶ 88). The cited reviews state “many positions are filled based on who you know” or who is “liked by Management[,]” and the company’s leadership “is not focused on the welfare of [the] employees.” (Id. (alterations adopted; other alteration added; quotation marks omitted)). Further, on July 16, 2019, BioReference Laboratories, Inc., a wholly owned subsidiary of OPKO, was sued for alleged discrimination and harassment based on race. (See id. ¶¶ 75, 78). BioReference settled the lawsuit in November 2020. (See id. ¶ 78).

In addition to failing to diversify the Board or ensure compliance with state and federal antidiscrimination laws (see id. ¶¶ 7, 74, 86–87, 89), the Individual Defendants have failed to maintain adequate internal controls and continue appointing an ineffective independent auditor to assess OPKO’s internal controls regarding diversity and antidiscrimination (see id. ¶¶ 12–13, 92). Despite their knowledge of the alleged discriminatory misconduct — by virtue of their participation in and failure to rectify or monitor it — the Individual Defendants caused OPKO to make misleading statements in three of its annual Proxy Statements regarding the company’s commitment to diversity and compliance with its Code of Conduct. (See id. ¶¶ 4, 8, 13). OPKO’s 2018, 2019, and 2020 Proxy Statements assured investors the Code of Conduct “applies to all employees, officers, and directors of the [c]ompany[;]” but failed to disclose the Code of Conduct

was not followed due to the Individual Defendants’ discrimination in filling Board positions and their failure to report such Code violations. (Id. ¶¶ 95, 103, 111 (alterations added; quotation marks omitted)). The Proxy Statements also represented that the Board values “diversity of knowledge base, professional experience[,] and skills[;] and the Corporate Governance and Nominating Committee takes these qualities into account when considering director nominees for recommendation to the Board.” (Id. ¶¶ 96, 104, 112 (alterations added; quotation marks omitted)). Yet, the Proxy Statements (1) failed to disclose that the Individual Defendants were repeatedly refusing to hire or nominate Black, Latinx, or other underrepresented minorities to the Board or executive management team (see id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Doris Staehr v. John R. Alm
269 F. App'x 888 (Eleventh Circuit, 2008)
Bryant v. Avado Brands, Inc.
187 F.3d 1271 (Eleventh Circuit, 1999)
Rosenberg v. Gould
554 F.3d 962 (Eleventh Circuit, 2009)
Sinaltrainal v. Coca-Cola Company
578 F.3d 1252 (Eleventh Circuit, 2009)
Mills v. Electric Auto-Lite Co.
396 U.S. 375 (Supreme Court, 1970)
Virginia Bankshares, Inc. v. Sandberg
501 U.S. 1083 (Supreme Court, 1991)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
American Dental Assoc. v. Cigna Corp.
605 F.3d 1283 (Eleventh Circuit, 2010)
Mohamad v. Palestinian Authority
132 S. Ct. 1702 (Supreme Court, 2012)
Little Gem Life Sciences LLC v. Orphan Medical, Inc.
537 F.3d 913 (Eighth Circuit, 2008)
Seminaris v. Landa
662 A.2d 1350 (Court of Chancery of Delaware, 1995)
In Re Citigroup Inc. Shareholder Derivative Litigation
964 A.2d 106 (Court of Chancery of Delaware, 2009)
Ryan v. Gifford
918 A.2d 341 (Court of Chancery of Delaware, 2007)
Beam Ex Rel. M. Stewart Living v. Stewart
845 A.2d 1040 (Supreme Court of Delaware, 2004)
Miguel v. State
924 A.2d 3 (Supreme Court of Rhode Island, 2007)
In Re Caremark International Inc. Derivative Litigation
698 A.2d 959 (Court of Chancery of Delaware, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
Lee v. Frost, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lee-v-frost-flsd-2021.